---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-26-000018"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:27:53.751831+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111

## Summary
- Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.
- FDA granted RMAT designation to KB707 for advanced NSCLC and Fast Track to KB111 for Hailey-Hailey disease.
- Positive CORAL-1 CF data: inhaled KB407 achieved 29.4%-42.1% airway cell transduction; CORAL-3 enrollment expected 1H 2026.
- Cash and investments $955.9M; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.
- VYJUVEK has over 660 US reimbursement approvals; launched in Germany, France, Japan; Israel agreement signed.

## SEC filing metadata
- accession: 0001711279-26-000018
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/0001711279-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/krys-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-26-000018
- JSON: https://secwatch.observer/filing/0001711279-26-000018.json
- Plain text: https://secwatch.observer/filing/0001711279-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.